Naltrexone long-acting formulation in the treatment of alcohol dependence by Johnson, Bankole A
© 2007 Dove Medical Press Limited.   All rights reserved
Therapeutics and Clinical Risk Management 2007:3(5) 741–749 741
REVIEW
Naltrexone long-acting formulation
in the treatment of alcohol dependence
Correspondence: Bankole A Johnson
Alumni Professor and Chairman, 
Department of Psychiatry and 
Neurobehavioral Sciences,
University of Virginia, PO Box 800623, 
Charlottesville, VA 22908-0623, USA
Tel +1 434 924 5457
Fax +1 434 244 7565
Email bankolejohnson@virginia.edu
Bankole A Johnson
Department of Psychiatry and 
Neurobehavioral Sciences, University 
of Virginia, Charlottesville, VA, USA
Abstract: While oral naltrexone has a demonstrated ability to decrease alcohol reinforcement, 
it also has pharmacotherapeutic limitations, such as a small treatment effect size, adverse events, 
and plasma level ﬂ  uctuations. The pharmacokinetic proﬁ  le of naltrexone could be enhanced 
by intramuscular administration, which would sustain its release over several weeks and keep 
plasma levels relatively constant, ie, low enough to minimize side effects but high enough to 
reduce drinking. Vivitrex®/Vivitrol® and Naltrel® are injectable naltrexone depot formulations 
that have been tested as possible medications for treating alcohol dependence. Their adverse-
event proﬁ  les appear to be less severe than that of oral naltrexone. Vivitrex®/Vivitrol® has 
demonstrated efﬁ  cacy at decreasing heavy drinking among alcohol-dependent males. Naltrel® 
helped to promote abstinence and decrease the incidence of relapse in two samples of alco-
hol-dependent subjects. The data on a third formulation, Depotrex®, are still limited. All three 
formulations require further study of their efﬁ  cacy.
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Introduction
The reinforcing effects of alcohol associated with its abuse liability are mediated 
by dopaminergic pathways that originate in the ventral tegmental area, relay to the 
nucleus accumbens with neuronal inputs from other limbic regions, and progress to 
the cortex (Wise and Bozarth 1987; Weiss and Porrino 2002; Koob 2003). Naltrexone, 
a mu-opioid receptor antagonist, decreases alcohol reinforcement via two mecha-
nisms: (1) suppression of alcohol-mediated beta-endorphin stimulation of dopamine 
neurons directly in the nucleus accumbens, and (2) reduction of beta-endorphin 
disinhibition of the tonic inhibition of dopamine cells by gamma-aminobutyric acid 
neurons in the ventral tegmental area (Spanagel and Zieglgansberger 1997; Johnson 
and Ait-Daoud 2000).
Srisurapanont and Jarusuraisin (2005), in a review of 27 randomized controlled 
clinical trials, reported that oral naltrexone was efﬁ  cacious at decreasing relapse and 
a return to heavy drinking among recently abstinent alcohol-dependent individuals, 
which is consistent with the above hypothesis. Yet, since the pharmacokinetic proper-
ties of oral naltrexone lead to signiﬁ  cant ﬂ  uctuations in plasma levels with oral daily 
dosing, its general effectiveness has been limited by two consequential factors. First, 
the low plasma trough level of oral naltrexone diminishes its efﬁ  cacy, which could 
explain why medication adherence above 85% is required in order for there to be a 
therapeutic response (Volpicelli et al 1997). Second, high peak levels are deemed 
responsible for adverse events (Croop et al 1997; King et al 1997), and up to 15% of 
oral naltrexone recipients drop out of treatment because of adverse events, especially 
nausea (Croop et al 1997).
The effectiveness of naltrexone also is limited by its small treatment effect 
size (Johnson and Ait-Daoud 2000; Feinn and Kranzler 2005), especially in newer Therapeutics and Clinical Risk Management 2007:3(5) 742
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and multi-site trials; the number needed to treat (ie, to see 
a difference from placebo) is 7 for decreasing the likelihood 
of relapse and 12 for decreasing the likelihood of returning 
to drinking (Srisurapanont and Jarusuraisin 2005). Never-
theless, subjects with the Asp40 allele of the mu-opioid 
receptor, as opposed to those with the Asn40 allelic type, 
might derive greater therapeutic beneﬁ  t than is seen in 
the averaged response (Oslin et al 2003). Further study is 
needed to conﬁ  rm these results.
Optimizing the pharmacokinetic proﬁ  le of naltrexone by 
developing a deep intramuscular injection that would release 
naltrexone over several weeks would, therefore, enhance its 
overall effectiveness. Consequently, plasma levels would 
remain relatively constant and low enough to reduce the 
incidence of adverse events yet high enough for the desired 
anti-drinking effects (Bartus et al 2003). In other words, 
while the effect size of naltrexone’s long-acting, intramus-
cular formulation would not be expected to exceed the effect 
size of oral naltrexone, the overall outcome would probably 
be enhanced by the increased compliance and longer exposure 
to a therapeutic dose. This review focuses on the therapeutic 
effects and pharmacological properties of two long-acting, 
injectable depot preparations of naltrexone – Vivitrex®, 
recently renamed Vivitrol® (Alkermes, Inc., Cambridge, 
MA, USA), and Naltrel® (DrugAbuse Sciences, Inc., Paris, 
France) – for treating alcohol dependence. Another depot 
formulation, Depotrex® (Biotek, Inc., Woburn, MA, USA), 
for which published data are limited, is also mentioned.
Table 1 provides a summary of the advantages and dis-
advantages of depot naltrexone preparations compared with 
oral naltrexone in alcohol-dependent individuals.
Currently available preparations
Properly formulated depot preparations can maintain 
relatively constant plasma levels for days or weeks because 
of the slow, timed release of the compound. Long-acting 
naltrexone depot formulations also are designed to minimize 
the high plasma peaks and exposure of the gastrointestinal 
tract to naltrexone that occur with the oral formulation. 
Thus, there is a reduction in nausea, the main adverse event 
associated with discontinuation of naltrexone treatment. 
Also, the relatively stable plasma levels of a naltrexone depot 
formulation help to maintain constant levels of mu-opioid 
receptor occupancy, and, importantly, this facilitates a 
linear pharmacodynamic response. Since alcohol-dependent 
individuals often are relatively non-compliant with regard to 
medication taking (Rohsenow et al 2000), spacing naltrexone 
injections at intervals of up to 4 weeks, thereby keeping 
plasma levels constant, should enhance compliance and 
promote greater efﬁ  cacy.
Vivitrex®/Vivitrol® is naltrexone formulated into 
poly-(lactide-co-glycolide) (Shive and Anderson 1997), 
small-diameter (100 µm), injectable microspheres, which 
contain other proprietary active moieties that lead to its 
extended-release properties lasting for several weeks (Lewis 
1990). In animal studies, these microspheres were suspended 
in 1 mL of an aqueous solution (3.0% low-viscosity 
carboxymethylcellulose, 0.9% saline, and 0.1% Tween-20), 
enabling injection of a 50 mg/kg dose of naltrexone (Bartus 
et al 2003). The plasma naltrexone level reached its peak 
at approximately 15 ng/mL by the third day post-injection, 
was sustained at approximately 12 ng/mL for another 
18 days, and then tapered off until it dipped below 1 ng/mL 
Table 1 Advantages and disadvantages of depot naltrexone preparations compared with oral naltrexone in alcohol-dependent 
individuals
Advantages of depot naltrexone preparations compared with  Disadvantages of depot naltrexone preparations compared
oral naltrexone  with oral naltrexone
• Efﬁ  cacy is not compromised since there are   •  An apparent gender disparity in efﬁ  cacy
 not  signiﬁ  cant ﬂ  uctuations in plasma levels     (with men receiving the greater beneﬁ  t)
  causing low trough levels    requires further exploration
•  Adverse events, particularly nausea, are not  •  Certain adverse events, such as erythema,
  increased by high peak levels that would result from the     induration, and injection site reactions, are unique to
 plasma  level  ﬂ  uctuations    the depot formulations
•  Since injections are spaced 4-weeks apart,   •  Vivitrol® is contraindicated in patients
  problems with compliance are minimized    receiving opioid analgesics
•  The simplicity of supervision and administration   •  More health care providers must be involved to
  might make the depot formulations suitable for    ensure proper administration
  forensic settings  •  Depot formulations could be cost prohibitive for many
•  Patients who will be in situations where oral     patients
  naltrexone is unavailable can receive treatment  •  Delivery of psychosocial support might be
        needed more often than the monthly injectionsTherapeutics and Clinical Risk Management 2007:3(5) 743
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14 days after that (Bartus et al 2003). Vivitrex® resulted in 
an approximate 70% reduction, compared with placebo, of 
morphine-induced analgesia in the hot-plate test for approxi-
mately 3 weeks – an effect that disappeared by 4 weeks after 
injection. The expected rise in mu-receptor density, caused by 
Vivitrex®-induced antagonist blockade, was evaluated using 
[D-ala2, N-methyl-phe4, glycol5] enkephalin ([3H]DAMGO). 
This revealed that there was a 110% increase, compared with 
placebo, in mu-receptor density, from 5 days after the injec-
tion until 33 days later, most prominently in the thalamus, 
nucleus accumbens, dorsal raphe nucleus, and striatum. 
Vivitrex®, therefore, appears to block effectively the central 
mu-opioid receptors for a period of approximately 4 weeks 
after the injection (Bartus et al 2003).
Fewer data on Naltrel® than on Vivitrex®/Vivitrol® exist 
in the public domain. Naltrel® consists of naltrexone incor-
porated within microspheres of poly-(DL-lactide) polymer. 
These microspheres are contained in single-dose vials and 
suspended in a diluent comprising mannitol, carboxymeth-
ylcellulose, polysorbate 80, and water for injection. When 
metabolized, the polylactide polymer produces water and 
carbon dioxide. Degradation of the microspheres causes 
naltrexone to be released (Kranzler et al 2004).
A lesser-known third formulation, Depotrex®, is dis-
cussed brieﬂ  y in the Clinical Results section below.
Pharmacodynamics
and pharmacokinetics
The marked analgesic response to morphine in the hot-plate 
paradigm in rats was blocked by Vivitrex® (50 mg/kg) from 
the ﬁ  rst day of injection until 4 weeks later. An injection 
of Vivitrex® 5 weeks after the ﬁ  rst injection led to suppres-
sion of morphine analgesia for another 4 weeks (Bartus 
et al 2003). When Vivitrex® was injected subcutaneously, 
plasma naltrexone peaked at approximately 15 ng/mL after 
approximately 3 days; following intramuscular injection, it 
peaked at 19 ng/mL, also after approximately 3 days. Mean 
plasma naltrexone levels were 12 to 14 ng/mL for the next 
3 weeks regardless of the route of administration, and they 
were detectable until 5 weeks after the injection. After the 
administration of a competitive mu-receptor antagonist, there 
usually is a neuroadaptive upregulation of these receptors 
(Lahti and Collins 1978; Zukin et al 1982). This pharmacody-
namic response was quantiﬁ  ed by measuring the mu-receptor 
density with [3H]DAMGO radioligand autoradiography fol-
lowing the administration of Vivitrex®. After a single injec-
tion, signiﬁ  cant increases in mu-receptor density occurred, 
especially in the midbrain and striatum a week later and in the 
neocortex a month later; these were sustained for 2–4 weeks. 
Similar results were seen in immunochemistry studies, but 
with relatively smaller increases, which ranged from 10% 
to 40% (Bartus et al 2003). Importantly, the amount of mu-
receptor upregulation after injection of Vivitrex® appears 
similar to the amount after at least 4 weeks of oral naltrexone 
administration (Giordano et al 1990). In view of the fact 
that suppression of morphine analgesia also occurred in the 
hot-plate paradigm for 5 weeks after the administration of 
a single Vivitrex® injection, it is reasonable to suggest that 
a pharmacologically relevant dose of Vivitrex®/Vivitrol® 
continues its pharmacodynamic effect of blocking central 
mu-receptors for up to 1 month post-injection.
Johnson et al (2004) showed, in a double-blind, 
placebo-controlled, randomized, multi-site, 16 week study 
of 30 alcohol-dependent individuals, that the 25 subjects 
receiving an intramuscular injection of Vivitrex® (400 mg) 
every 4 weeks for 4 months had a mean plasma 6-beta-
naltrexol (naltrexone’s major metabolite) trough level of 
3.0 ng/mL and a mean naltrexone trough level of 1.3 ng/mL. 
In contrast, an earlier study found that – 16 hours after 
administration of oral naltrexone (50 mg) – subjects had a 
mean serum 6-beta-naltrexol level of 24.9 ng/mL (McCaul 
et al 2000). The ﬁ  ndings of King et al (1997) showed mean 
urinary concentrations of 29.0 µg/mg for 6-beta-naltrexol 
and 2.9 µg/mg for naltrexone, 3 hours after oral administra-
tion of naltrexone (50 mg) in 24 male moderate-to-heavy 
social drinkers.
Galloway et al (2005) demonstrated, in an open-label, 
single-site, 6 week study of 16 alcohol-dependent indi-
viduals receiving just one intramuscular injection of Naltrel® 
(300 mg), that serum naltrexone levels increased to a peak of 
approximately 2.04 ng/mL at 2 weeks and dissipated slowly 
to 0.58 ng/mL over the next 4 weeks. Plasma naltrexone and 
6-beta-naltrexol levels at week 4 were approximately 0.75 
and 2.2 ng/mL, respectively. These levels were proportion-
ately (ie, to dose) less than those found in the Vivitrex® study 
by Johnson et al (2004).
In humans, the peak plasma concentration of long-acting 
naltrexone depot formulations is greater than that of oral nal-
trexone during the days immediately after the injection. The 
advantage of these formulations with respect to tolerability, 
therefore, may be that such peaks just occur early in treatment 
with the depot preparations whereas they occur daily with 
oral naltrexone. The lack of ﬁ  rst-pass metabolism with the 
long-acting preparations, with diminished 6-beta-naltrexol 
levels, also might lead to an improved adverse-event proﬁ  le 
as increased levels of beta-naltrexol have been associated Therapeutics and Clinical Risk Management 2007:3(5) 744
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with a greater severity and frequency of naltrexone-related 
adverse events (King et al 1997).
Thus, preclinical and human studies provide a phar-
macodynamic and pharmacokinetic basis for the monthly 
injection of a long-acting naltrexone depot formulation as 
treatment for alcohol dependence through the blockade of 
mu-opioid receptors.
Clinical results
Clinical trials involving alcohol-dependent individuals have 
examined the efﬁ  cacy, safety, and tolerability of Naltrel® and 
Vivitrex®/Vivitrol®.
Naltrel®
The ﬁ  rst published study on the efﬁ  cacy, safety, and toler-
ability of Naltrel® for treating alcohol dependence comprised 
a multi-site, double-blind, 12 week clinical trial. One hun-
dred ﬁ  fty-eight alcohol-dependent men and women were 
assigned to receive Naltrel® and 157 received placebo, both 
accompanied by motivation enhancement-based psycho-
social support, every 4 weeks (Kranzler et al 2004). The 
ﬁ  rst Naltrel® dose consisted of one injection of 150 mg in 
each buttock, and each dose thereafter was just 150 mg. 
Placebo was identical in number and volume of injections 
but did not contain the active compound. Generally, Naltrel® 
appeared to be well tolerated and safe. Side effects that were 
reported signiﬁ  cantly more frequently in the Naltrel® group 
than in the placebo group included injection site reactions, 
chest pain, and upper abdominal pain. Irritability, however, 
was more common after placebo than after injection of 
Naltrel®. There were 13 dropouts (8.2%) in the Naltrel® 
group and only 6 dropouts (3.8%) in the placebo group; 
the subjects’ reasons for discontinuing treatment, however, 
were similar between the groups. Naltrel® recipients were 
more likely than placebo recipients to have a higher mean 
number of cumulative abstinent days (52.8 days, 95% 
CI 48.5–57.2 days, vs 45.6 days, 95% CI 41.1–50.0 days, 
respectively; p = 0.018) and a longer median time to ﬁ  rst 
drink (5 days, 95% CI 3–9 days, vs 3 days, 95% CI 2–4 
days, respectively; p = 0.003). The effects of gender on treat-
ment outcome were not examined, probably because of the 
relatively small sample size (Kranzler et al 2004).
A single-site, 6 week, open-label trial studied 16 alcohol-
dependent individuals who were given a single intramuscular 
dose of Naltrel® (300 mg) (Galloway et al 2005). Of the 
198 adverse events that were reported, 17 were rated as 
severe, including fatigue, gastrointestinal pain, irritability, 
nausea, somnolence (2 reports), headache (4 reports from 
3 subjects), injection site pain, injection site mass, lethargy, 
depression, increased gamma-glutamyl transferase (GGT) 
level (an index of heavy drinking) (Conigrave et al 2002), 
back pain, and ﬂ  atulence. There were no serious adverse 
events. Also, the trend was for participants’ drinking out-
comes to improve between enrollment and the end of the 
trial (Galloway et al 2005).
Since the Naltrel® formulation has shown promise as an 
efﬁ  cacious medication for treating alcohol dependence, it 
deserves further study. Early ﬁ  ndings indicate that Naltrel® is 
safe and well tolerated, and its adverse-event proﬁ  le appears 
to be milder than that reported for oral naltrexone. Additional 
data are needed regarding the effects of gender on treatment 
outcome. Future studies also should show whether Naltrel® is 
likely to cause injection site-related allergic-type reactions.
Vivitrex®/Vivitrol®
The ﬁ  rst published study on the initial efﬁ  cacy, safety, and 
tolerability of Vivitrex® for treating alcohol dependence was 
a double-blind, placebo-controlled, randomized, multi-site, 
16 week clinical trial (Johnson et al 2004). Twenty-ﬁ  ve 
alcohol-dependent individuals were assigned to receive intra-
muscular injections of Vivitrex® (400 mg) every 4 weeks, 
while ﬁ  ve participants received placebo via the same route 
of administration every 4 weeks. Vivitrex® appeared to be 
relatively safe and well tolerated; the most common adverse 
events were non-speciﬁ  c abdominal pain, nausea, pain at 
the injection site, and headaches. Two Vivitrex® recipients 
and zero placebo recipients discontinued treatment because 
of side effects. One participant dropped out due to indura-
tion at the injection site, and one was discontinued by the 
research staff because of an allergic reaction that resulted 
in angioedema, which resolved soon after the participant 
stopped taking the medication. Even though any conclu-
sions regarding efﬁ  cacy must take into consideration the 
study’s unbalanced cell design, it did appear that Vivitrex® 
was more likely than placebo to lead to a lower percentage 
of heavy drinking days (ie, 11.7% vs 25.3%, respectively). 
In the exercise of scientiﬁ  c caution, no inferential statistical 
testing was conducted on these descriptive values. Addition-
ally, participants in both the Vivitrex® and placebo groups 
demonstrated improved drinking outcomes between enroll-
ment and study end (Johnson et al 2004).
The efﬁ  cacy, safety, and tolerability of Vivitrex® were 
later studied in a placebo-controlled, double-blind, ran-
domized, multi-site, 24 week clinical trial (Garbutt et al 
2005). Intramuscular injections of high-dose Vivitrex® 
(380 mg) (n = 205), low-dose Vivitrex® (190 mg) (n = 210), Therapeutics and Clinical Risk Management 2007:3(5) 745
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or matching placebo (n = 209), along with low-intensity 
psychosocial support, were administered to alcohol-
dependent men and women every 4 weeks. Participants 
who received high-dose Vivitrex® were signiﬁ  cantly more 
likely than placebo recipients to report the adverse events of 
decreased appetite, nausea, pain at the injection site, dizzi-
ness, and fatigue. The low-dose Vivitrex® and placebo groups 
experienced adverse events at a similar frequency. Although 
14.1% of the high-dose Vivitrex® recipients dropped out of 
treatment, only 6.7% of the low-dose Vivitrex® and placebo 
groups did so. Injection site reactions, headaches, and nausea 
were the most common reasons given for discontinuing treat-
ment. Two high-dose Vivitrex® recipients had serious adverse 
events caused by an interstitial pneumonia and allergic-type 
eosinophilic pneumonia, both of which resolved after medical 
treatment. The high-dose Vivitrex® group, averaged between 
men and women, had a signiﬁ  cantly lower percentage of 
heavy drinking days than did placebo recipients (hazard 
ratio [HR] 0.75, 95% CI 0.60–0.94; p = 0.02). An analysis 
by gender, however, demonstrated that the only improvement 
in drinking outcomes among high-dose Vivitrex® recipients 
was in men (HR 0.56, 95% CI 0.41–0.77; p  0.001) and 
not women (HR 1.23, 95% CI 0.85–1.78; p = 0.28). These 
ﬁ  ndings demonstrate that although women in the high-dose 
Vivitrex® group versus the placebo group reported a 23% 
relative increase in percentage of heavy drinking, men in 
the high-dose Vivitrex® group reported a relative decrease of 
44% in the same variable. High-dose Vivitrex® and placebo 
recipients did not differ signiﬁ  cantly in GGT level, and low-
dose Vivitrex® and placebo recipients did not experience a 
signiﬁ  cant difference in GGT level or drinking outcomes 
(Garbutt et al 2005).
At least four points need to be made concerning the evi-
dence that Vivitrex®/Vivitrol® can decrease heavy drinking in 
men but not women (Johnson 2006). First, since individuals 
with alcohol dependence in their family history have reportedly 
experienced the best results with oral naltrexone (Monterosso 
et al 2001), it is tempting to speculate that male subjects in the 
Garbutt et al (2005) trial may have responded to Vivitrex® for 
the same reason. Comparative rates of family history of alco-
holism between men and women, however, were not given. 
Hence, future studies testing the efﬁ  cacy of Vivitrex®/Vivitrol® 
should investigate any potential interaction between familial 
alcoholism (or related variables including age of alcoholism 
onset) and treatment outcome.
Second, Vivitrex® injections might have been more likely 
in women than in men to be delivered subcutaneously instead 
of intramuscularly, thereby slowing absorption, since women 
tend to have a relatively higher percentage of body fat (Blaak 
2001). Indeed, in a study by Kiefer et al (2005), drinking 
outcomes appeared to be better for women than for men 
receiving oral naltrexone. Since Garbutt et al (2005) did not 
study pharmacokinetic data, a report comparing the kinetic 
proﬁ  le of Vivitrex®/Vivitrol® between women and men 
would be required to exclude this possibility.
Third, alcohol-dependent men and women enrolled 
in clinical trials perhaps cannot be compared directly as 
they might differ on non-drinking outcomes, including 
familial pressure to change, rates of affective disorder, 
or individual motivation to achieve treatment objectives. 
There is no evidence, however, to suggest that the women 
enrolled in this trial were atypical of women participat-
ing in pharmacotherapy trials for the treatment of alcohol 
dependence. Moreover, among the enrolled men, there was 
probably heterogeneity on these same factors. Attempts 
to match women and men who are enrolled in pharmaco-
therapy trials for treating alcohol dependence on multiple 
non-drinking-related factors would not be practical and 
would lead to the same conclusion, ie, that the therapeutic 
effect of Vivitrex®/Vivitrol® to diminish heavy drinking 
among alcohol-dependent men does not translate to alcohol-
dependent women. Subjects who participate in pharmaco-
therapy trials for treating alcohol dependence are mostly 
men, and the relatively small sample sizes of single-site 
studies do not allow meaningful statistical comparisons of 
drinking outcomes between women and men. Of the two 
important trials that resulted in US Food and Drug Admin-
istration approval of oral naltrexone for treating alcohol 
dependence (O’Malley et al 1992; Volpicelli et al 1992), 
only the O’Malley et al (1992) study included women, but 
not in large enough numbers to permit gender comparisons. 
Given the multitude of published studies testing oral naltrex-
one for the treatment of alcohol dependence (Srisurapanont 
and Jarusuraisin 2005), a meta-analytic approach to 
examining for a gender effect on treatment outcome would 
be of scientiﬁ  c interest. If oral naltrexone has demonstrated 
similar efﬁ  cacy between women and men, then the absence 
of an effect for Vivitrex® in women might be a result of 
the fact that oral naltrexone and Vivitrex®/Vivitrol® are 
prepared and administered differently. If, on the other 
hand, meta-analytic studies reveal that oral naltrexone, like 
Vivitrex®/Vivitrol®, exhibits greater efﬁ  cacy for men than 
for women, then it is plausible that such ﬁ  ndings would be 
related to common pharmacodynamic interaction factors. 
A greater understanding of such factors is necessary for 
optimization of treatment delivery.Therapeutics and Clinical Risk Management 2007:3(5) 746
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Fourth, pharmacotherapy studies of naltrexone or its 
analogues for treatment of alcohol dependence usually 
reveal a small to medium effect size. Thus, the differential 
efﬁ  cacy for Vivitrex® between men and women might have 
happened by chance.
The importance of the ﬁ  ndings of allergic-type interactions 
with Vivitrex® is uncertain. Based upon the two cases of 
pneumonia reported by Garbutt et al (2005) and the one case 
of angioedema reported by Johnson et al (2004), the allergic-
type reaction rate for Vivitrex®/Vivitrol® would be 1 per 218 
study subjects. Additional investigation of oral naltrexone 
and naloxone (a structurally similar medication designed for 
intravenous injection) is needed to determine their allergic-
type reaction rates. Comparing the Vivitrex®/Vivitrol® 
ﬁ  ndings directly with any such results, however, would be 
complicated by differences in study population size, disease 
states, and length of exposure, among other factors. A prudent 
analysis would require extensive monitoring of the potential 
for allergic-type reactions after Vivitrex®/Vivitrol® admin-
istration in future clinical trials. Since Vivitrex®/Vivitrol® 
cannot be removed from a subject’s body after it is injected, 
and any allergic-type reactions would be prolonged as a 
result of the formulation’s long duration of action, a practical 
approach to naltrexone treatment might (depending upon the 
allergic-type reaction rates for oral naltrexone and naloxone) 
be to use a small “test dose” of Vivitrex®/Vivitrol® before 
delivering the full therapeutic dose a few days later.
Clinical evidence suggests that Vivitrex®/Vivitrol® can 
diminish heavy drinking among men but not women. The 
reason for this difference in efﬁ  cacy is still unclear, as is the 
pathophysiological signiﬁ  cance of the potential for allergic-
type reactions with Vivitrex®/Vivitrol®; thus, further investi-
gation is warranted. Overall, Vivitrex®/Vivitrol® appears to 
be safe and well tolerated, with a milder adverse-event proﬁ  le 
than oral naltrexone. Future studies should compare directly 
the side-effect proﬁ  les of Vivitrex®/Vivitrol® and Naltrel®.
Depotrex®
Published data on another depot naltrexone formulation, 
Depotrex®, are limited. Depotrex® appears to cause a 
stable and sustained increase in plasma naltrexone levels. 
It antagonizes mu-opioid receptors with few side effects 
(Heishman et al 1994; Alim et al 1995). Comparative dose-
ranging pharmacokinetic data on Depotrex® have been 
reported in a study of 12 heroin-dependent individuals 
(Comer et al 2002). Depotrex® (low and high doses of 192 
and 384 mg, respectively) kept plasma naltrexone levels 
above 1 ng/mL for 3 and 4 weeks, respectively. Mean peak 
levels for the low and high Depotrex® doses were 3.8 and 
8.9 ng/mL, respectively. Plasma beta-naltrexol levels were 
proportionately higher but were undetectable 5 weeks 
following administration. Both the low and high doses 
antagonized heroin-induced positive subjective effects. The 
primary adverse event reported was mild discomfort at the 
injection site, with no irritation or erythema (Comer et al 
2002). Previously, Kranzler et al (1998) reported promis-
ing ﬁ  ndings showing that the administration of Depotrex® 
(206 mg) was associated with a prolonged increase in plasma 
naltrexone, similar to the Comer et al (2002) study in heroin 
addicts. Moreover, their study highlighted the efﬁ  cacy of 
Depotrex®, compared with placebo, at reducing heavy drink-
ing among alcohol-dependent individuals; nevertheless, 
injection site reactions including induration were observed 
in some participants (Kranzler et al 1998). Additional studies 
on this promising formulation are needed.
Discussion
While the naltrexone long-acting formulations discussed 
herein have the beneﬁ  t of lower adverse-event proﬁ  les and 
necessitate fewer visits to a treatment center than would be 
needed for the administration of oral naltrexone, their use 
does require that more health care providers be trained. For 
instance, injections must be administered properly to decrease 
the possibility of local site reactions, which could, in turn, 
diminish compliance. Moreover, the number of physicians 
or nurses might have to be increased so that providers are on 
hand to administer the injections and to assess and triage any 
medical complications that may occur (Johnson 2006).
Although depression and other psychiatric problems are 
not listed among the contraindications for injectable naltrex-
one in the Vivitrol® package insert (Alkermes, Inc. 2005), 
adverse events of a suicidal nature were reported infrequently 
in controlled trials among Vivitrol®-treated patients (1% vs 0 
in the placebo group), and depressed mood was twice as likely 
(10% vs 5%) for Vivitrol® (380 mg) recipients vs placebo 
recipients in a 24 week controlled trial. Hence, alcohol-
dependent patients taking Vivitrol® should be monitored for 
depression or suicidal ideation (Alkermes, Inc. 2005).
Vivitrol® is contraindicated in patients who are receiving 
opioid analgesics. If pain management becomes necessary 
in an emergency situation, Vivitrol® recipients should be 
given regional analgesia, conscious sedation with a benzo-
diazepine, and non-opioid analgesics or general anesthesia. 
In situations requiring opioid analgesia, administration of a 
rapidly acting opioid analgesic that minimizes the duration 
of respiratory depression is recommended, with the amount Therapeutics and Clinical Risk Management 2007:3(5) 747
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of analgesic titrated to the patient’s needs. These patients 
should be closely monitored by personnel who are trained in 
cardiopulmonary resuscitation (Alkermes, Inc. 2005).
Thus far, no precedent exists in the psychiatric ﬁ  eld for 
administering a medication intramuscularly instead of orally. 
Practitioners, therefore, might use these long-acting depot 
preparations only if a “trial” of oral naltrexone has failed 
because of low compliance. Furthermore, it also is possible 
that, in real-world generic clinics as opposed to clinical trial 
settings in a research facility, patients might be less likely to 
consent to injections for the treatment of alcohol dependence 
due to injection phobia, relatively less individual attention 
paid by medical staff, or a lower intensity of psychosocial 
support provided by health professionals. Providers might 
also consider a “trial” of oral naltrexone to guarantee early 
detection of any adverse events (Johnson 2006).
If long-acting depot formulations of naltrexone are 
approved by the US Food and Drug Administration, their 
widespread use might be limited because of cost. Uneven 
insurance coverage has hampered the use of oral naltrexone 
in many parts of the US. While the prices of the depot formu-
lations have not yet been announced, their daily cost might 
exceed that of oral naltrexone. Hence, these preparations 
might be less accessible to uninsured patients who cannot 
pay on their own (Johnson 2006).
Treatment providers should not avoid delivering regular, 
adequate psychosocial support to alcohol-dependent indi-
viduals just because monthly depot injections are convenient. 
Before being introduced, the long-acting formulations would 
have been assessed against a background of psychosocial 
support. In other words, information on drinking outcomes 
could not be gleaned from simply administering monthly 
injections without providing psychosocial support. Psy-
chosocial support should be scheduled to coincide with the 
monthly visits to the treatment center (ie, when injections 
are administered) or more frequently for some patients. 
When treatment for alcohol-dependent individuals is initi-
ated, additional psychosocial support might be needed to 
provide a safety net in the event of relapse, establish a strong 
therapeutic alliance, and ensure delivery of a high standard 
of care. Thus, treatment centers that use long-acting depot 
formulations for the treatment of alcohol dependence must 
be ﬂ  exible in monitoring the adequacy of patient care and 
delivering psychosocial support (Johnson 2006).
Naltrexone’s efﬁ  cacy might be enhanced by the pre-
scription of other adjunctive medications, eg, the glutamate 
antagonist acamprosate (Kiefer et al 2003) or the serotonin-
3 receptor antagonist ondansetron (Johnson et al 2000), 
although further conﬁ  rmation of these results is needed. The 
combination of other medications with a long-acting depot 
naltrexone preparation instead of with oral naltrexone would 
be advantageous in terms of: (1) increasing compliance since 
no additional tablets would be needed, (2) decreasing the like-
lihood of kinetic interactions, and (3) enhancing the potential 
for added pharmacodynamic response against a platform of 
stable plasma naltrexone levels (Johnson 2006).
The population that could beneﬁ  t the most from long-
acting naltrexone depot formulations includes alcohol-
dependent individuals who experience prolonged or marked 
adverse events from taking oral naltrexone and those who 
have low compliance with medication taking because of 
non-speciﬁ  c factors such as memory impairment (Johnson 
2006). Such patients previously might have failed to beneﬁ  t 
from outpatient treatment programs involving adjunctive 
medication.
Alcohol-dependent individuals who have experienced 
relatively low therapeutic effects from oral naltrexone also 
might beneﬁ  t from a long-acting formulation (Johnson 2006). 
Before abandoning the continued use of naltrexone for such 
patients, a practitioner could provide a “trial” of a depot 
preparation to rule out ﬂ  uctuating plasma naltrexone levels 
as a potential cause of inefﬁ  cacy.
Other suitable candidates for long-acting depot prepara-
tions of naltrexone might include alcohol-dependent indi-
viduals with a comorbid psychiatric disorder (Johnson 2006). 
The depot formulation would limit the need for additional pill 
taking to that required for managing the comorbid psychiatric 
disorder, which could enhance compliance.
A potentially controversial use of long-acting naltrexone 
formulations would be in drug courts or forensic facilities. 
Supervision and enforcement of a pharmacotherapeutic regi-
men would be easier in the case of a depot preparation rather 
than an oral medication (Johnson 2006). Alcohol-dependent 
individuals who have committed offenses could be offered a 
choice between imprisonment and supervised treatment with 
a naltrexone depot preparation. This suggestion, however, 
raises serious ethical considerations regarding the rights of 
individuals to make rational choices that concern their medi-
cal treatment, as well as the potential for “drift” or abuse. 
While alcohol-dependent individuals in forensic settings 
often lack adequate treatment (Lapham 2004/2005), and 
long-acting depot formulations of naltrexone would be a 
valuable adjunct to existing protocols, clear guidelines need 
to be established to prevent misuse of the medication.
Alcohol-dependent individuals who anticipate being in 
situations where oral naltrexone will be unavailable (and Therapeutics and Clinical Risk Management 2007:3(5) 748
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thus difﬁ  cult to obtain if it is lost), such as military personnel 
on short assignments or people traveling overseas, would 
also be suitable candidates for long-acting naltrexone depot 
preparations. Furthermore, treatment with such a formulation 
could be a stopgap measure between hospital detoxiﬁ  cation 
and outpatient referral, so that a patient would still be treated 
with medication during that time frame.
No direct comparisons of efficacy have been made 
between oral and depot naltrexone preparations. Nonethe-
less, among alcohol-dependent men who have been given 
Vivitrex®/Vivitrol® or in those using Naltrel®, estimates of 
efﬁ  cacy appear to be comparable, with a small to medium 
effect size. The prescribing decision, therefore, probably 
will be guided by patient selection, history, characteristics, 
and preferences.
Summary and conclusions
Long-acting naltrexone depot formulations provide a new 
opportunity to improve the efﬁ  cacy, delivery, and safety of 
treatment to alcohol-dependent individuals. These prepara-
tions are designed to enhance medication compliance, diminish 
adverse events, and increase efﬁ  cacy by reducing ﬂ  uctuating 
plasma naltrexone levels. Practitioners who wish to conﬁ  rm 
that this therapeutic approach (ie, mu-opioid blockade) lacks 
efﬁ  cacy among their alcohol-dependent patients who have 
failed a previous “trial” of oral naltrexone might also ﬁ  nd 
depot preparations to be useful. Forensic settings, which 
represent an underserved population of alcohol-dependent 
individuals who often do not receive adequate pharmaco-
therapy, might derive beneﬁ  t from the use of naltrexone 
depot formulations; however, clear guidelines for such use 
are needed to maintain ethical standards of medical care and 
protect the rights of patients to choose their treatment.
Vivitrex® has demonstrated efficacy at significantly 
decreasing heavy drinking among alcohol-dependent men; 
however, more data are needed to determine whether these 
therapeutic beneﬁ  ts apply to alcohol-dependent women. 
Naltrel® appears to be efﬁ  cacious at promoting abstinence 
and diminishing the likelihood of relapse among alcohol-
dependent individuals. The sample size of the only published 
double-blind clinical trial, however, was not large enough to 
allow for meaningful determination of the effects of gender 
on treatment outcome. Hence, it remains to be seen whether, 
as with Vivitrex®/Vivitrol®, Naltrel®’s efﬁ  cacy at improving 
drinking outcomes is greater for one gender than for the 
other. Long-acting depot formulations of naltrexone might 
someday be combined with other putative therapeutic agents 
for maximization of treatment effect.
Adverse events associated with the naltrexone depot 
formulations appear to be slightly milder than those arising 
from use of oral naltrexone, but there has yet to be a direct 
comparison between the oral and depot formulations within 
the same clinical trial. Also, phase-IV-type effectiveness stud-
ies in generic treatment settings are needed to help ascertain 
whether the adverse events associated only with the depot 
preparation, eg, erythema, induration, and injection site reac-
tions, negate its apparent advantages over oral naltrexone. 
Further study is needed to determine whether the tendency of 
either of these formulations to be associated with unexpected 
adverse or allergic reactions is clinically important.
It has become increasingly clear from pharmacotherapy 
trials, including those involving depot naltrexone formula-
tions, that the greatest treatment effect is derived from study 
enrollment, regardless of treatment condition (Johnson et al 
2005). This can cause statistically signiﬁ  cant differences in 
treatment effect between the active medication and placebo 
groups to seem relatively small from a clinical perspective. 
While the initial “placebo” or non-speciﬁ  c treatment effect 
might appear to be hindering an accurate measure of the 
efﬁ  cacy of a putative therapeutic medication versus pla-
cebo, it might be more appropriate to think of this effect as 
an aid to the clinical setting that needs to be harnessed and 
understood. Optimization of non-speciﬁ  c treatment effects 
and understanding how they interact with medications or 
psychosocial treatment are worthy goals in the development 
of methodologies for future clinical trials.
Long-acting naltrexone depot preparations might be 
ideal medications for alcohol-dependent individuals who 
have failed to beneﬁ  t from outpatient treatment because of 
prolonged adverse events experienced with oral naltrexone, 
its inefﬁ  cacy resulting from ﬂ  uctuating plasma naltrexone 
levels, or poor compliance with medication taking. They 
also could be useful in forensic settings due to the simplicity 
of administration and supervision, provided that all relevant 
ethical considerations ﬁ  rst are addressed and resolved.
Meanwhile, questions pertaining to the safety and efﬁ  cacy 
of the available depot formulations remain. The results 
heretofore are encouraging but mixed, and there appears to 
be a gender-based variation in efﬁ  cacy that deserves further 
exploration. Studies comparing the efﬁ  cacy of the depot 
and oral naltrexone preparations are warranted. Additional 
clinical trials of both Naltrel® and Vivitrex®/Vivitrol® would 
be beneﬁ  cial. Perhaps depot preparations of naltrexone could 
be combined with other medications to maximize efﬁ  cacy, 
pending the results of future investigations. Extension of 
the current knowledge regarding long-acting naltrexone Therapeutics and Clinical Risk Management 2007:3(5) 749
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formulations will help practitioners to prescribe the best 
formulation for treating alcohol-dependent individuals.
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